The Study Of Gamma-glutamyltransferase To Metabolic Syndrome And Coronary Heart Disease

Objective: This study of the metabolic syndrome (International Diabetes Federation in 2005 published diagnostic criteria for metabolic syndrome -worldwide, "China targets" as the standard diagnosis) and diagnosis of coronary heart disease patients, the serumγ-Valley, GT enzyme for the observed changes in the metabolic syndrome among patients with non-metabolic syndrome; coronary heart disease among patients with coronary heart disease patients with non-whether there is statistically significant. Body mass index on coronary heart disease, abdominal circumference, blood lipids, fasting blood glucose, blood pressure and many other factors. To analyze of gamma-Glutamyltransferas for the metabolic syndrome and coronary heart disease related, metabolic syndrome and coronary artery disease to provide more evidence.Methods: Select 2008-3 to 2009-12 patients admitted to our hospital by the Department of Cardiology, or in the hospital patients who were not in hospital the first time. All subjects were asked in detail about coronary heart disease by a health professional, family history, smoking history, drinking history, routine 18-lead synchronization electrocardiogram, blood pressure, weight, height, abdominal circumference, calculated body mass index of all subjects in the determination of the former were fasting for 12 hours or more, in the early morning in fasting peripheral venous blood taken.Hitachi 7600 biochemical laboratory biochemical tests to measure the glutamyltranspetidase (GGT), fasting plasma glucose (FPG), plasma total cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol (HDL- C), low density lipoprotein (LDL-C), serum creatinine, liver and kidney function checks. In screening a variety of information caused by the prohibited person, a total of 332 cases. IDF released the MS diagnostic application indicators to judge China, diagnostic results were organized into tables, divided into metabolic syndrome group (A Group) and non-metabolic syndrome group (B); be selected according to specific diagnostic groups were divided into coronary heart disease group ( C) and non-CHD group (D group). Respectively A, B group and C, D groups of glutamyltranspetidase were compared. All data were analyzed statistically applications SPSS16.0 software, data analysis and calculation through T test F value, the data do not meet the normal distribution, correlation analysis using Spearman's rho test, multivariate analysis using Logistic regression analysis, P<0.05 for those significant difference.Results: Metabolic syndrome group (A group) and non-metabolic syndrome group (B group) compared to serum GGT level parametric analysis, (because they do not fit the normal distribution so the information with non-parametric rank correlation test) between the two groups statistically significant. Spearman's rho correlation coefficient r = 0.215, P = 0.000 <0.05 (bilateral), or that the prevalence of serum GGT levels and between MS-related; and non-MS patients with no correlation. With the elevated levels of serum GGT, and the more closely related to MS. CHD group (C group) and non-CHD group (D group) to serum GGT level parametric analysis, no significant statistical difference between the two groups. Correlation coefficient r = 0.000, P = 0.991 (both sides), or that the level of serum GGT was no correlation with CHD.Conclusions: The level of serum GGT and metabolic syndrome are relevant not only elevated GGT levels, increasing incidence of metabolic syndrome, but for patients diagnosed with MS, GGT elevated levels of various factors on the aggregation of MS not significant, and no gender differences. GGT levels of the same patients group was not statistically associated with CHD. Multivariate analysis showed that serum GGT levels in patients with CHD age, ALT, ALP, HDL and alcohol consumption, relevant, and therefore can not explain the occurrence of GGT with the development of coronary heart disease totally not related, in addition consider the CHD group of confirmed cases for the horizontal study, it can not explain the level of serum GGT was no relationship between CHD prevalence.